Schultze Joachim L
Molekulare Tumorbiologie und Tumorimmunologie Medizinische Klinik I , Universitätsklinikum Universität zu Köln, Köln, Germany.
Med Klin (Munich). 2006 Aug 15;101(8):617-23. doi: 10.1007/s00063-006-1091-z.
The revolutionary development in the biosciences during the last 15 years--including the sequencing of the human genome and multiple other genomes as well the possibility of massive parallel analysis of thousands of data points within a single experiment--have greatly improved our understanding of the pathophysiology of tumor development and progression as well as metastasis.
The further development of genomic technology for routine clinical use is slowly but steadily leading to a paradigm shift: the currently used tumor definition based on pathologic and histological assessment is replaced by molecularly defined tumor subtypes. This is an essential prerequisite for the development of molecularly defined individualized therapies in oncology leading to more effective treatments with less severe side effects. The first molecularly defined drugs (targeted drugs) have already entered the clinical arena. However, not only diagnostics and therapy on oncology will change dramatically in the future, but also the way we have to organize oncology itself.
The integration of genomics and information technologies will require the establishment of interdisciplinary teams beyond the already established collaborations between surgeons, radiotherapists and medical oncologists.
过去15年里，生物科学领域取得了革命性进展，包括人类基因组及多个其他基因组的测序，以及在单个实验中对数千个数据点进行大规模平行分析的可能性，这极大地增进了我们对肿瘤发生、发展及转移的病理生理学的理解。
用于常规临床的基因组技术的进一步发展正在缓慢但稳步地引发一种范式转变：当前基于病理和组织学评估的肿瘤定义正被分子定义的肿瘤亚型所取代。这是肿瘤学中开发分子定义的个体化疗法的必要前提，从而实现更有效治疗且副作用更小。首批分子定义的药物（靶向药物）已进入临床领域。然而，未来不仅肿瘤学的诊断和治疗将发生巨大变化，而且我们组织肿瘤学自身的方式也将改变。
基因组学与信息技术的整合将需要建立跨学科团队，这超越了外科医生、放疗科医生和肿瘤内科医生之间已有的合作。
